Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lumateperone

lumateperone

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of lumateperone

5 trials tracked of lumateperone: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 107 citations.

5Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5
  1. Phase 3 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally Completed · 107 cited
  2. Phase 3 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder Completed · 15 cited
  3. Phase 3 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed · 6 cited
  4. Phase 3 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed
  5. Phase 3 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults
Psychiatry FDA Approval
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults FDA approves Caplyta to treat schizophrenia in adults
FDA approved Caplyta (lumateperone) for treatment of schizophrenia in adults.
The FDA approved Caplyta (lumateperone) for treating schizophrenia in adults.
FDA Apr 29, 2026